

Torrent - Recall of Iosartan/hydrochlorothiazide

- On January 22, 2019, <u>Torrent announced</u> an expansion of their voluntary, consumer-level recall of losartan tablets to include several lots of <u>losartan/hydrochlorothiazide (HCTZ)</u> tablets due to the detection of trace amounts of an unexpected impurity, identified as N-nitrosodiethylamine (NDEA), found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs.
 - Torrent initially announced a consumer-level recall of losartan on December 20, 2018. The recall was then expanded on January 3, 2019 to include additional lots of losartan.
- NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and
 industrial processes, and has been classified as a probable human carcinogen as per International
 Agency for Research on Cancer classification.
 - Refer to the FDA site for updates regarding angiotensin II receptor blocker recalls.
- The products included in the expanded recall are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Losartan/HCTZ 50/12.5	13668-116-90	BP02C008 (3/2019)
mg tablets	13668-116-10	BEF7D006 (3/2020)
Losartan/HCTZ 100/12.5 mg tablets	13668-117-90	BX35C020 (5/2019);
		BX35C049 (8/2019)
	13668-117-10	BX35C023 (5/2019);
		BX35C022 (5/2019)

- Losartan/HCTZ tablets are used for the treatment of hypertension (HTN) and to reduce the risk of stroke in patients with HTN and left ventricular hypertrophy.
- Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on losartan/HCTZ should continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled losartan/HCTZ.
- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.
- For more information regarding this recall, contact Torrent at 1-800-912-9561.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.